Furthermore, lenvatinib was also found to regulate pathways modulating antitumor immunity, including the reduction of tumor PD-L1 expression levels and Treg differentiation by blocking Fibroblast growth factor receptor-4 (FGFR4) (40) and reducing the Treg proportion via TGF-b pathway inhibition (41). The gene discussed is FGFR4; the disease is neoplasm.